Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The rationale for this study is to evaluate and understand the variability of a generic
alternative of abacavir, dolutegravir and lamivudine dispersible tablets for PEPFAR
submission to aide in the development of pivotal studies.